News

Novartis’s anti-CD20 monoclonal antibody has been shown to increase the odds of patients with multiple sclerosis achieving no evidence of disease activity status by more than 3-fold in the first year and more than 8-fold in the second year.

This AUPN Leading Edge Special Episode features Clifton L. Gooch, MD, and Justin C. McArthur, MBBS, MPH, who discuss how their institutions and departments are approaching operations amid COVID-19. [LISTEN TIME: 21 minutes]

Plasma neurofilament light chain (pNfL) may serve as a prognostic tool to assess the risk of developing permanent disability in multiple sclerosis.

The staff neurologist, Vice-Chair of Operations, and Quality Improvement Officer at Cleveland Clinic Neurological Institute detailed his experience managing patients with various conditions through a telemedicine platform.

The professor of neurology at NYU Langone shares her thoughts on the clinical data that has been released so far on patients with COVID-19.

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic detailed the need to incorporate interdisciplinary care and behavioral medicine in commonplace MS practice.

Neurology News Network for the week ending May 23, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 22, 2020.

The data included more than 2000 brains and approximately 400 cerebrospinal fluid samples, and showed that a protein network module linked to glucose metabolism was also elevated in cerebrospinal fluid in early stages of the disease.

The director of the multiple sclerosis research unit at Ottawa Hospital discussed stem cell therapies being explored in multiple sclerosis, and which patients may be eligible for these treatments.

The study author, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital discussed the findings of a pooled analysis of the ACHIEVE I and II studies of ubrogepant.

The drug is the first on-demand off episode treatment to be administered sublingually.

The first study to examine the impact on real-world outcomes and costs of switching patients with MS from Copaxone to Glatopa revealed few significant differences.